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SUMMARY
Sphingolipids (SLs) are an integral part of all eukaryotic cellular membranes. In addition, they have indispensable functions as
signallingmolecules controlling a myriad of cellular events. Disruption of either the de novo synthesis or the degradation path-
ways has been shown to have detrimental effects. The earlier identification of selective inhibitors of fungal SL biosynthesis
promised potent broad-spectrum anti-fungal agents, which later encouraged testing some of those agents against protozoan
parasites. In this review we focus on the key enzymes of the SL de novo biosynthetic pathway in protozoan parasites of the
Apicomplexa and Kinetoplastidae, outlining the divergence and interconnection between host and pathogen metabolism.
The druggability of the SL biosynthesis is considered, alongside recent technology advances that will enable the dissection
and analyses of this pathway in the parasitic protozoa. The future impact of these advances for the development of new
therapeutics for both globally threatening and neglected infectious diseases is potentially profound.
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INTRODUCTION
Protozoan parasites and the global burden of their
diseases
Protozoa (kingdom Protista) are single-cell organisms
that can be free-living or parasitic in nature (Baron,
1996). Out of more than 50 000 protozoan species
that have been described to-date, relatively few have
been identified as major contributors to the global
burden of human diseases (Kuris, 2012) and animal
agriculture (Dubey, 1977). The protozoa represent
19% of all human parasites (83 out of 437 species to-
date) and are associated with 30% of parasite-induced
human morbidity-mortality (Kuris, 2012).
Of the four groups of infectious protozoa (CDC,
2017), the Mastigophora (flagellates) and Sporozoa
contain theKinetoplastidae andApicomplexa, respect-
ively. It is to these two phyla that belong many of
the causative agents of disease: Mastigophora – the
insect vector-borne kinetoplastids Trypanosoma
brucei (Human African Trypanosomiasis, HAT),
Leishmania spp. (leishmaniasis, cutaneous andvisceral)
and Trypanosoma cruzi (American trypanosomiasis,
Chagas’ disease); Sporozoa – the apicomplexan
Toxoplasma gondii (toxoplasmosis), Cryptosporidium
spp. (cryptosporidiosis) andEimeria spp. (coccidiosis
inpoultry andcattle),Theileria spp. (EastCoastFever
in cattle) andPlasmodium spp., includingPlasmodium
falciparum the causative agent of severe malaria and
one of the ‘Big Three’ global infectious diseases
alongside HIV and tuberculosis (Torgerson &
Macpherson, 2011).
Historically, the diseases caused by some of these
parasites have been classified as Neglected Tropical
Diseases (NTDs) or Neglected Zoonotic Diseases
(King, 2011) and were associated with the classical
model of the ‘poverty trap’ covering tropical and
sub-tropical regions in Africa, Latin America and
the Indian subcontinent (Kuris, 2012). However,
with global changes in climate and human demo-
graphics and associated practices, the classical
models do not promise safe boundaries that might
contain and/or stop the further global spread of
many of these parasitic diseases (Colwell et al. 2011).
The problems associated with these pathogens are
further aggravated by the lack of effective vaccines
(Dumonteil, 2007; Innes et al. 2011; McAllister,
2014; Black&Mansfield, 2016) and the paucity of reli-
able drugs (Zofou et al. 2014), in addition to the
difficulties of vector or reservoir control (Colwell
et al. 2011). Therefore, there is a recognized need to
find new therapeutic targets in these causative agents
in order to develop effective treatment regimens to
avoid potentially catastrophic outbreaks, both in
terms of human health and economic impact.
This review presents sphingolipid (SL) biosyn-
thesis and ceramide (CER) homoeostasis as a poten-
tial gold mine of tractable drug targets for these
protozoan parasites.
State-of-the-art treatment of apicomplexan and
kinetoplastid diseases
In general, available treatments for the diseases
caused by the Kinetoplastidae and Apicomplexa
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are outdated (if not historic), with relatively few
examples that were introduced recently, toxic and
require a long treatment regimen, and therefore
close monitoring of patients.
The kinetoplastid pathogens in focus here all
cause NTDs and as such there are significant pro-
blems with the available drug regimens:
Leishmania spp. The treatment of leishmaniasis
often requires a long course of intravenous pentavalent
antimony drugs (e.g. Glucantime and Pentostam),
aminosidine (paromomycin) or liposomal amphoter-
icin B (Croft & Coombs, 2003; Center for Food
Security and Public Health, 2004; WHO, 2004;
Kedzierski et al. 2009). The most recent addition
was the orally available miltefosine (Sunder et al.
2002; Verma & Dey, 2004), originally developed as
anti-neoplastic agent. Despite its teratogenic effects
(Sunder et al. 2002), due to the lack of other
effective medications, it has been registered and is
now used in India, Colombia, Guatemala and
Germany (Soto & Berman, 2006). Other regimens of
treatment include Pentamidine (Bray et al. 2003),
allopurinol, dapsone, fluconazole, itraconazole and
ketoconazole. However, to-date all available che-
motherapeutic agents suffer from being toxic
(Chappuis et al. 2007) or inaccessible, both geographic-
ally and financially, in endemic areas where public
health is under-resourced, poor and underdeveloped.
Additionally, the lack of effective vaccines (de
Oliveira et al. 2009) and the alarming emergence of
resistance to these drugs (Croft et al. 2006), combined
with the short-lived prevention resulting from
applying measures such as vector and reservoir
host control (WHO, 2004; Figueiredo et al. 2012),
demand an intensive search for alternative anti-
leishmanials to enable effective treatment and
control.
Trypanosoma brucei. Another compelling example
of the shortcomings of available treatments is HAT
(Mina et al. 2009; Buckner et al. 2012), where
there is a lack of effective vaccines (Black &
Mansfield, 2016) and treatment depends on the stage
of the disease. Whilst in the first stage, the drugs
used are less toxic, easier to administer and more
effective, treatment in the second stage requires
drugs that can cross the blood-brain barrier, specifi-
cally the arsenates (Gibaud & Jaouen, 2010), making
them considerably more toxic and complex to admin-
ister (Babokhov et al. 2013). Currently, four drugs are
registered for HAT treatment and are provided free of
charge to endemic countries through a WHO private
partnership with Sanofi-Aventis (Pentamidine, melar-
soprol and eflornithine) and Bayer AG (suramin)
(Schmidt et al. 2012). Unfortunately, all of them
exhibit a broad range of adverse effects. Moreover,
treatment regimens are usually highly restrictive,
particularly in the second stage of the disease,
requiring hospital-based I.V. treatment with continu-
ous monitoring.
Trypanosoma cruzi. Despite their toxic side-
effects, nifurtimox and benznidazole are the only
licenced drugs available for treatment of Chagas’
disease (Carabarin-Lima et al. 2013; Bermudez
et al. 2016), with the latter being the first choice
due to its lower side effects. Also, benznidazole has
been implemented in the treatment of women
before pregnancy in order to prevent/reduce vertical
transmission (Carabarin-Lima et al. 2013; Murcia
et al. 2013). Due to the lack alternatives, efforts
have been directed towards implementing different
treatment regimens in order to reduce toxicity, e.g.
intermittent administration schedules, combination
therapy and re-purposing of commercial drugs
(Bermudez et al. 2016).
Management of apicomplexan infections is also chal-
lenging and faces many of the same shortcomings
encountered in the treatment of kinetoplastid
infections.
Toxoplasma gondii. Treatment regimens for toxo-
plasmosis patients have essentially remained the
same since the 1950s (Eyles & Coleman, 1953).
They largely depend on the repurposing of antibacter-
ials (sulfadiazine, spiramycin and clindamycin) and
antimalarials (pyrimethamine and atovaquone)
(Opremcak et al. 1992; Andrews et al. 2014; Antczak
et al. 2016) in combination, therapies that target para-
site folic acid synthesis, protein synthesis or oxidative
phosphorylation (Greif et al. 2001; Antczak et al.
2016). Most of these chemotherapeutics are not
readily bioavailable at the site of infection (e.g.
unable to cross the blood-brain barrier); cannot be
administered by patients with hypersensitivity to sul-
phonamides; have suspected teratogenic properties
(Montoya & Remington, 2008; Paquet & Yudin,
2013); are threatened by the emergence of resistance
(Sims, 2009); or require adjuvant therapies (folinic
acid supplement) to minimize toxic side effects (for a
detailed review see Antczak et al. 2016).
Toxoplasmosis is a representative of the urgent need
for new antiprotozoal targets. In addition to the fact
thatT. gondii is estimated to infect 2–3 billion people
worldwide (Welti et al. 2007), its treatment is
complicated due to two main factors: (a) the parasite
undergoes a complex life cycle with two predomin-
ant forms in the human host, namely, tachyzoites
(proliferative form) and bradyzoites (encysted form,
chronic toxoplasmosis); (b) bradyzoite burden is
widespread but usually asymptomatic, although it
has been associated with psychiatric disorders
(Webster et al. 2013). However, in immunocom-
promised individuals encysted T. gondii transform
into proliferative tachyzoite forms causing symp-
tomatic disease, toxoplasmic encephalitis. As such
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T. gondii is an opportunistic parasite. Notably, all
the above-mentioned drugs act only against the
tachyzoite stage with no notable effect against
encysted bradyzoites (Antczak et al. 2016). Recent
data from our laboratory (Alqaisi et al. 2017) and
others (Sonda et al. 2005) have shown that the
Aureobasidin A and analogous depsipeptides,
known to target yeast SL biosynthesis (Wuts et al.
2015), exhibit activity against bradyzoite T. gondii.
This class of compounds may offer a potential treat-
ment for chronic toxoplasmosis and, perhaps, some
psychiatric disorders; although the mechanism of
action is not via inhibition of parasite SL biosyn-
thesis and is yet to be elucidated (Alqaisi et al. 2017).
Plasmodium falciparum. Falciparum malaria
remains one of the ‘Big Three’, most prevalent and
deadly infectious diseases across tropical and sub-
tropical regions, with an estimated 154–289 million
cases in 2010 (212 million cases in 2015), and 660
000 (429 000 in 2015) associated deaths; although
the actual numbers might be even higher (Biamonte
et al. 2013; WHO, 2016).
Similar to T. gondii, Plasmodium parasite undergoes
a complex life cycle with different stages in different
organs of the host, rendering treatment challenging:
sporozoites and schizonts in the liver, and mero-
zoites, trophozoites and gametocytes in the blood
(Dechy-Cabaret & Benoit-Vical, 2012). Artemisinin-
based combination therapies (ACTs) are the standard
for treating malaria cases with typical partner drugs
including lumefantrine and piperaquine, e.g.
Coartem™ (Novartis) and Eurartesim™ (Sigma-
Tau) (Biamonte et al. 2013). Other regimens include
the use of parenteral artesunate (severe malaria)
(Dondorp et al. 2010a), primaquine (liver and trans-
mission, gametocyte, stages) (Dondorp, 2013),
mefloquine and sulfadoxine/pyrimethamine in com-
bination (effective as single dose antimalarial drug)
(Biamonte et al. 2013) and atovaquone/proguanil,
Malarone™ (GlaxoSmith Kline), as a prophylactic
treatment.
However, although combination therapies have
now been adopted, resistance against many existing
antimalarials has been observed since the 1950s
(Bishop, 1951; Hallinan, 1953; Sandosham et al.
1964) and remains a severe threat (Rieckmann &
Cheng, 2002; Chinappi et al. 2010; Dondorp et al.
2010b; Newton et al. 2016; Parija, 2016; Menard &
Dondorp, 2017; Zhou et al. 2017). This bleak view
of the future of available anti-malarial chemothera-
peutics makes it imperative to invest more efforts
in identifying new potent chemotypes that will
offer both efficacy and safety.
Cryptosporidium spp. Like T. gondii, Cryptospo-
ridium parvum and Cryptosporidium hominis usually
cause a self-limiting disease in healthy individuals
but represent a manifest problem in immuno-
compromised patients, particularly those with
AIDS, where infection leads to acute and protracted
life-threatening gastroenteritis (Chen et al. 2002).
More recent data have led to a radical reassessment
of the impact of cryptosporidiosis, with the number
of Cryptosporidium-attributable diarrhoea episodes
estimated at >7·5 million in children aged <24
months in sub-Saharan Africa and South Asia where
infection is estimated to contribute to >250 000 infant
deaths per year (Sow et al. 2016). Current treatment
of cryptosporidiosis relies on a single FDA-approved
drug, nitazoxanide, which has limited efficacy in
those most at risk. More recently, the repurposing of
antimalarials, e.g. quinolones and allopurinols, has
been proposed (Gamo et al. 2010; Chellan et al. 2017).
The distinctive metabolic features of this parasite
from other apicomplexan organisms, e.g. no
plastid-derived apicoplast and the absence of the
citrate cycle and cytochrome-based respiratory
chain (Ryan & Hijjawi, 2015), confer several limita-
tions for the identification of targets necessary for the
development of anticryptosporidial drugs. However,
the core metabolic pathways, e.g. energy metabolism
and lipid synthesis are still present and exhibit high
level of divergence from the mammalian host, thus
presenting an opportunity to identify new drug
targets that promise effective and selective treatment
(Chellan et al. 2017).
The biological significance of SLs
SLs are a class of lipids that are ubiquitous in
eukaryotic cell membranes, particularly the plasma
membrane, as well as in some prokaryotic organisms
and viruses (Merrill & Sandhoff, 2002). Since their
earliest characterization by Thudichum (1884), they
have been a subject of controversy. Initially, they had
been considered of structural importance only;
however, over the last couple of decades, several
reports have revealed their indispensability to a pleth-
ora of functions including, but not limited to, the
formation of structural domains, polarized cellular
trafficking, signal transduction, cell growth, differen-
tiation and apoptosis (Huwiler et al. 2000; Ohanian &
Ohanian, 2001; Cuvillier, 2002; Pettus et al. 2002;
Buccoliero & Futerman, 2003).
SLs consist structurally of a sphingoid base back-
bone, e.g. sphingosine (SPH) that can beN-acylated
to form CER. To the latter, a variety of head groups:
charged, neutral, phosphorylated and/or glycosy-
lated can be attached to form complex SLs, e.g.
sphingomyelin (SM), as the primary complex mam-
malian SL; and inositol phosphorylceramide (IPC)
in fungi, plants and numerous protozoa (Fig. 1).
These molecules have both polar and non-polar
regions giving rise to their amphipathic character,
which accounts for their tendency to aggregate into
membranous structures, yet retaining the interfacial
ability to interact with various partners, e.g.
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involvement of glycosphingolipids (GSLs) in cellular
recognition complexes, cell adhesion and the regula-
tion of cell growth (Gurr et al. 2002).
Furthermore, the diversity of their chemical struc-
tures allows for distinctive roles within cellular
metabolism, e.g. the signalling functions of SPH
and CER vs sphingosine-1-phosphate (S1P) and cer-
amide-1-phosphate (C1P) (Merrill & Sandhoff,
2002; Metzler, 2003).
SLs as indispensable structural components
The unique structural features of SLs (the free
3-hydroxy group, the amide functionality and the
C4–C5 trans double bond) affect their biophysical
properties rendering these molecules different from
their glycerolipid counterparts, i.e. SM vs phosphat-
idylcholine (PC) (Boggs, 1980, 1987; Talbott et al.,
2000; Ramstedt & Slotte, 2002). Such interfacial
differences give complex SLs, such as SM, the
unique ability to form both intra- and intermolecular
hydrogen bonds (Bruzik, 1988) that are fine-tuned
by the trans double bond (Ramstedt & Slotte,
2002). This ability is reflected in the tendency of
SLs to cluster rather than behave like typical
‘fluid’ membrane lipids. Naturally occurring SLs
undergo the Lβ (gel phase) to Lα (lamellar phase)
transition near the physiological temperature of
37 °C, in contrast, this transition for naturally
occurring glycerolipids is near or below 0 °C.
Additionally, the long saturated alkyl chains of SLs
allow them to pack tightly with sterols, stabilized
by hydrogen bonding (Ramstedt & Slotte, 2002),
to form laterally compact hydrophobic micro-
domains commonly known as ‘lipid rafts’
(Futerman & Hannun, 2004). Similar results have
been reported with the fungal/plant counterpart of
SM, IPC, where it was shown that IPC was able to
form sterol containing ordered domains in model
systems (Björkbom et al. 2010). These membrane
micro-domains can readily segregate from the more
disordered and expanded domains of unsaturated
Fig. 1. Illustration of the predominant species of complex sphingolipid in organisms from different evolutionary clades:
EPC in Drosophila; SM in mammals; and IPC in Leishmania and T. cruzi (as representatives of protozoan parasites) and
in fungi and plants. IPC is absent from Mammalian cells but essential for many pathogenic organisms (red box).
Glycosylated sphingolipids are also ubiquitous across different species. Backbone chain length is commonly C18 derived
from palmitoyl-CoA. Mammals M, Fungi and Plants FP, Leishmania spp. L, Trypanosoma cruzi Tc, Trypanosoma brucei
Tb, Toxoplasma gondii Tg and Plasmodium falciparum Pf. *Denotes developmental regulation. EPC, ethanolamine
phosphorylceramide; IPC, inositol phosphorylceramide; SM, sphingomyelin.
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acyl chains of glycerolipids (Merrill & Sandhoff,
2002). They have been proposed to function in a
diverse array of processes from polarised trafficking
of lipid modified proteins (Brown & London,
1998) and the stabilization of other types of bio-
logical structures such as lamellar bodies, to the
assembly and activation of signal transduction com-
plexes (Brown & London, 2000; Magee et al. 2002;
Pierce, 2002; Vance & Vance, 2002; Hannun &
Obeid, 2008). They have also been involved in
the formation of detergent-insoluble gel-phase
domains (Ramstedt & Slotte, 2002) via the extensive
hydrogen-bonding network in the head groups of
GSLs that have been implicated during the forma-
tion of ‘caveolae’ and surface recognition (Merrill
& Sandhoff, 2002).
SLs as indispensable signalling agents
SLs can also function as bioactive signalling mole-
cules due to their biophysical properties, e.g. the
low pKa (7–8) of SPH allows it to remain partially
uncharged at physiological pH retaining the ability
to move across membranes (Merrill & Sandhoff,
2002). Likewise, CER, a neutral species, is able to
freely flip flop across membranes (Hannun &
Obeid, 2008). Many studies have produced evi-
dence of such signalling functions, e.g. SPH
exerts pleiotropic effects on protein kinases; CER
mediates many cell-stress responses, including the
regulation of apoptosis (Georgopapadakou, 2000);
and S1P has crucial roles in cell survival, cell
migration and inflammation (Hannun & Obeid,
2008)
SL metabolism and the rationale for druggability
The indispensability of SLs for a myriad of cellular
processes and functions, ranging from structural
integrity to signalling events, makes it is unsurpris-
ing that the SL biosynthesis is highly conserved in
all eukaryotes where it is, alongside its proposed reg-
ulators (Holthuis et al. 2006), an essential pathway
(Heung et al. 2006; Sutterwala et al. 2007). This
has lead the pathway to be considered vital for proto-
zoan pathogenesis and, therefore, a drug target; e.g.
SM synthase activity in Plasmodium (Heung et al.
2006). In order to characterise the druggability of
protozoan SL biosynthesis, the mammalian pathway,
as the most studied system, will be used as the refer-
ence model in the following discussions.
SL metabolism constitutes a highly complex
network involving critical intersections with various
other pathways, particularly glycerolipid biosynthesis
(Holthuis & Menon, 2014). CER represents the
corner stone for both biosynthesis and catabolism,
modulating cell fate (Hannun & Obeid, 2008).
Dysregulation of either SL biosynthesis or catabol-
ism could result in cell death, e.g. of protozoan
parasites (Yatsu, 1971; Brady, 1978; Chen et al. 1999;
Merrill & Sandhoff, 2002), however here our focus
will be on the former pathway.
Considering the central position of CER, the
druggability of SL metabolism revolves around dys-
regulation of ‘Ceramide Homeostasis’ (Young et al.
2012) which in turn leads to ripple effects perturbing
the balance between the pro-apoptotic CER and the
mitogenic diacylglycerol (DAG), consequently
determining cell fate (Fig. 2) – a mechanism that
has been associated with resistance to anti-cancer
treatments (Ségui et al. 2006) and has been reported
in protozoan parasites, e.g. Plasmodium (Pankova-
Kholmyansky et al. 2003; Labaied et al. 2004).
The characterisation of several key enzymes
involved in SL de novo biosynthesis has revealed
divergence between mammalian and protozoan
species. Thus, attention has been given to the
exploitation of the SL biosynthetic pathway (para-
site and/or host) for new drug targets or regimens
(Sugimoto et al. 2004; Zhang et al. 2005; Denny
et al. 2006; Tanaka et al. 2007; Pruett et al. 2008;
Mina et al. 2009; Tatematsu et al. 2011; Young
et al. 2012).
SL METABOLISM
The key steps in de novo biosynthesis
SL de novo biosynthesis can be simplified into three
key steps: a gate-keeper and two cell fate modulator
steps. The former comprises the up-stream rate-lim-
iting step of the condensation of acyl-CoA and L-
serine, in the endoplasmic reticulum (ER) via
serine palmitoyltransferase (SPT), to produce dihy-
drosphingosine. The latter comprises first the for-
mation of CER in the ER by the action of
ceramide synthase (CerS), and then the formation
of complex SLs in the Golgi. These products vary
depending on the species, and are formed under
the catalysis of what could be generically termed
SL synthases: SM synthase in mammals and IPC
synthase in fungi, plants and protozoa. It is worth
mentioning that another Golgi localized metabolic
pathway results in the formation of glycosylated
CER species, and also contributes to the regulation
CER levels (Holthuis & Menon, 2014) (Fig. 2).
Protozoan parasites vs host: differences &
opportunities
The cross-species differences encountered in the
first, SPT-catalysed, step are mostly minor in
terms of the chemical structure of the product;
mainly due to the chain length of the acyl-CoA uti-
lised in the reaction, e.g. myristoyl-CoA (in
Leishmania spp. amongst other odd sphingoid base
lengths (Hsu et al. 2007)) and palmitoyl-CoA, with
the latter more predominant across the Eukaryota
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(in mammals, Plasmodium and T. brucei) (Richmond
et al. 2010; Botté et al. 2013). Further differences
may be apparent with respect to the catalysing
enzyme, SPT (vide infra). However, clear divergence
is observed in the second and the third steps, both
of which represent a cell-fate modulator process.
CerSs exhibit differential preferences for the chain
length of the acyl-CoA substrate (Park et al. 2014)
and its hydroxylation pattern (Layre & Moody,
2013), with 6 isoforms present in humans suggesting
a different role for each CER species produced
(Levy & Futerman, 2010; Figueiredo et al. 2012).
To-date, one or, maximum, two genes encoding
CerS function have been identified in protozoan
parasite species (Koeller & Heise, 2011). However,
most interesting is the variation in the complex SL
formed in the Golgi, reflecting significant differences
in the active site of the SL synthases catalysing the
transfer reaction. The divergence of the protozoal
complex SL synthases, and the synthetic products,
with respect to the mammalian host, may provide
opportunities to design selective inhibitors.
Previously, this step has been validated as a promising
drug target in fungi using aureobasidin A (AbA)
(Fig. 2) (Denny et al. 2006).
Serine palmitoyl transferase (SPT)
SPTs are members of the pyridoxal 5′-phosphate
(PLP)-dependent (Sandmeier et al. 1994) α-oxoa-
mine synthase family and share a conserved motif
(T[FL][GTS]K[SAG][FLV]G) around the PLP-
binding lysine (in bold) (Young et al. 2012). SPT
catalyses the first rate-limiting step in the de novo
biosynthesis of SLs (Weiss & Stoffel, 1997; Hojjati
et al. 2005) (Fig. 2), a reaction involving the decar-
boxylative Claisen-like condensation of serine and
an acyl-CoA (Lowther et al. 2012), to yield the
sphingoid base backbone, 3-ketodihydrosphingosine
(3-KDS) (Hanada, 2003; Raman et al. 2009;
Lowther et al. 2012). Therefore, SPT represents
the ‘Gatekeeper’ of the SL biosynthetic pathway.
All eukaryotic SPTs studied to date are ER-resi-
dent and membrane bound with a heterodimeric
protein core consisting of two subunits sharing
∼20% identity: LCB1 and LCB2, ∼53 and ∼63
Fig. 2. Schematic representation of de novo sphingolipid metabolism. Three key steps are highlighted: (1) SPT,
evolutionary divergent in T. gondii; (2) CerS, fewer isoforms in protozoan parasite (c.f. 6 isoforms in mammals); SLS,
while predominantly synthesising SM in mammals and to a lesser extent EPC, orthologues in protozoan parasites
(Leishmania spp., T. brucei, T. cruzi andT. gondii) can synthesise IPC, an activity that is absent frommammalian cells and
the target of the highly specific fungal inhibitors shown. The scheme also illustrates the differential cellular effects of
ceramide vsDAG (diacylglycerol). Accumulation of ceramide elicits an apoptotic response while increasing concentrations
of DAG promotes cell growth. CerS, ceramide synthase; GluCerS, glucosylceramide synthase; SLS, sphingolipid
synthase; SPT, serine palmitoyltransferase; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI,
phosphatidylinositol; SM, sphingomyelin; EPC, ethanolamine phosphorylceramide and IPC, inositol
phosphorylceramide.
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kDa respectively (Hanada, 2003; Denny et al. 2004;
Han et al. 2004; Chen et al. 2006). The latter con-
tains the canonical PLP cofactor binding site while
the former has been suggested to be important for
complex stability (Lowther et al. 2012). In contrast,
the orthologous SPT from sphingomonad bacteria is
a soluble 45 kDa homodimer (Ikushiro et al. 2001).
SPT activity in apicomplexan parasites has been
detected and was proposed as a potential drug
target (Gerold & Schwarz, 2001; Bisanz et al. 2006;
Coppens, 2013), however the enzyme(s) responsible
have yet to be further characterized (Mina et al.
2017). In contrast, kinetoplastid parasites have
been shown to possess a heterodimeric SPT similar
to the mammalian orthologue (Denny et al. 2004).
Inhibiting SPT activity (e.g. using myriocin,
Fig. 2) results in various effects in different species.
Mammalian cells exhibited a loss of viability, with
a partial loss of SPT function resulting in a rare SL
metabolic disease, Hereditary Sensory Neuropathy
type I (HSN1) (Hanada, 2003). In contrast,
Saccharomyces cerevisiae were found to be relatively
tolerant (Nagiec et al. 1994), and Leishmania major
lacking LCB2 were viable but unable to differentiate
into infective metacyclic forms (Zhang et al. 2003).
However, T. brucei procyclic forms in which SPT
expression was reduced were non-viable (Fridberg
et al. 2008).
The SPT catalysed reaction product, 3KDS, is sub-
sequently reduced by 3-ketosphinganine reductase to
form sphinganine (dihydrosphingosine). Subsequent
minor metabolic differences are encountered across
different species; mainly concerning the order of the
hydroxylation (in fungi and higher plants) and acyl-
ation to produce CERs (Sugimoto et al. 2004).
Ceramide synthase
In all eukaryotic systems studied to date, CerSs are
ER-resident integral membrane proteins catalysing
the N-acetylation of dihydrosphingosine to produce
dihydroceramide, which is then oxidized to form
CER, the simplest SL species and a key bioactive
molecule in numerous cellular pathways (Lahari &
Futerman, 2007).
Mammalian CerSs are orthologues of longevity-
assurance genes, LAG1p and LAC1p identified in
yeast (Guillas et al. 2001). The eukaryotes studied
to date have been found to encode at least two
CerSs, with humans expressing six – each generating
CER with a defined acyl chain length (C18 to C26)
(Pewzner-Jung et al. 2006; Levy & Futerman,
2010). Whilst little is known regarding structure-
function relationships or regulation of CerS,, the
ubiquitous Lag1 motif has been shown to be import-
ant for functionality (Spassieva et al. 2006), likely
forming part of the active site.
Experimental evidence (from our laboratory and
others) has previously indicated the presence of
CerS activity in Leishmania spp (Zhang et al.,
2003; Denny et al., 2004, 2006) and in T. cruzi
(De Lederkremer et al. 2011). More recently
LAG1 orthologues have been identified and func-
tionally and molecularly characterized in the latter
parasite (Figueiredo et al. 2012). Other results indir-
ectly suggest the presence of such activity in T.
brucei (Patnaik et al. 1993; Richmond et al. 2010;
Smith & Bütikofer, 2010). Similarly, CerS activity
in the Apicomplexa has been inferred (Welti et al.
2007; Zhang et al. 2010; Pratt et al. 2013), but
remains unexplored.
Once formed in the ER, CER is transported, by
CER transfer protein CERT in mammals
(Kumagai et al. 2005; Kudo et al. 2010; Rao et al.
2014), to the Golgi apparatus where the synthesis
of complex SLs occurs (Ohanian & Ohanian, 2001;
Bromley et al. 2003; Bartke & Hannun, 2009; Pata
et al. 2010). ER CER concentration is kept under
tight control as accumulation of CER here has
been shown to result in induction of the mitochon-
drial apoptotic pathway (Vacaru et al. 2009;
Tafesse et al. 2014) via an unknown mechanism
(Bockelmann et al. 2015).
Sphingolipid synthase
In the Golgi, CER can be phosphorylated by CER
kinase (Rovina et al. 2009), glycosylated by glucosyl
or galactosyl CerS (Raas-Rothschild et al. 2004), or
acquire a variety of neutral or charged head groups
under the catalysis of what could be called generic-
ally SLSs, to form various complex phosphosphin-
golipids. Phylogenetic analyses have identified at
least 4 clades of SLS (Huitema et al. 2004; Denny
et al. 2006).
In mammals CER is a substrate for the SLS, SM
synthase, to produce SM (Huitema et al. 2004).
Whilst in fungi and higher plants phytoceramide is
utilized by a different SLS, IPC synthase, to
produce IPC as the principal phosphosphingolipid
(Nagiec et al. 1997; Wang et al. 2008). This land-
scape is significantly divergent when it comes to
protozoa.
In the kinetoplastid Leishmania spp. and T. cruzi,
CER acquires a phosphorylinositol head group from
phosphatidylinositol (PI) to produce IPC via IPC
synthase (Zhang et al. 2005; Denny et al. 2006;
Mina et al. 2010), although there are some reports
of SM in T. cruzi (Quiñones et al. 2004) (Fig. 2).
Whilst Leishmania encodes a single copy IPC syn-
thase, T. cruzi has two highly related copies
(Denny et al. 2006). Further divergence, and pos-
sible redundancy, is encountered in T. Brucei,
which harbours 4 genes that encode SLSs (Denny
et al. 2006; Sutterwala et al. 2008). This enzyme
portfolio results in a diverse profile of the complex
SL species (SM, IPC and ethanolamine phosophor-
ylceramide [EPC]) which are developmentally
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regulated during the life cycle of the parasite
(Sutterwala et al. 2008).
In apicomplexan parasites, previous reports have
indicated the presence of glycosyl-ceramide and
SM in P. falciparum and T. gondii, as summarized
in Zhang et al (2010). However, other findings
reported the presence of EPC in T. gondii (Welti
et al. 2007) and, more recently, IPC (Pratt et al.
2013). The latter study also characterized T. gondii
SLS as demonstrating IPC synthase activity in
vitro (Pratt et al. 2013).
The divergence of SLS function, with respect to
the host, seen in both kinetoplastid and apicom-
plexan protozoan parasites in intriguing and,
perhaps, indicated them as a tractable drug target.
In support of this hypothesis, ceramide-analogues
with anti-Plasmodium activity have already been
identified (Labaied et al. 2004).
In general, SLSs are Golgi-resident transmem-
brane proteins, presumed to have 6 transmembrane
domains with the active site facing the Golgi
lumen (Holthuis et al. 2006; Sutterwala et al.
2008). Those orthologues identified in kinetoplastids
demonstrated two conserved regions
(CGDX3SGHT & HYTXDVX3YX6FX2YH)
with respect to the animal SM synthases (Huitema
et al. 2004; Denny et al. 2006). These regions
contain the so-called the catalytic triad (two
Histidines and one Aspartate residues) that mediates
a nucleophilic attack on lipid phosphate ester during
the transferase/hydrolase activity (Mina et al. 2010).
Apicomplexan orthologues form a separate evolu-
tionary clade, yet retain the catalytic triad (Denny
et al. 2006; Pratt et al. 2013), as does the fungal
orthologue AUR1p (Heidler & Radding, 2000).
Further evidence for the essentiality of these resi-
dues was provided when mutation of the active his-
tidine of the triad was shown to deactivate fungal
IPC synthase and mammalian SM synthase-related
activity (Levine et al. 2000; Vacaru et al. 2009).
Furthermore, recently it has been shown that sub-
strate selectivity, and so the diversity of SLS activ-
ity, may depend on key residues close to the
transferase active residues or on a luminal loop of
the protein (Sevova et al. 2010; Kol et al. 2017).
In the Eukaryota SLS’s occupy a central position
at the intersection of glycerolipids (PI/PC/PE and
DAG) and SLs ([phyto]ceramide and IPC/SM/
EPC). Accordingly, these enzymes act as regulators
of a delicate balance between pro-apoptotic CER
and pro-mitogenic DAG (Holthuis et al. 2006).
The most significant previous example of SL bio-
synthesis inhibition as a drug target was reported in
fungi. Aureobasidin A (AbA), a depsipeptide, was
first reported by Ikai et al. (1991) and soon after its
antifungal properties were highlighted (Takesako
et al. 1993). The target gene was further character-
ized (Hashidaokado et al. 1995) revealing its identity
to be the IPC synthase (AUR1p). AbA is a specific
and potent (low nanomolar) inhibitor of the fungal
IPC synthase. This ushered in a new era in the
search for anti-fungal chemotherapeutics, position-
ing IPC synthase as a promising, broad spectrum,
anti-fungal drug target (Sugimoto et al. 2004).
Other specific inhibitors were later added to the
arsenal of fungal IPC synthase inhibitors: khafrefun-
gin (Mandala et al. 1997), rustmicin (Harris et al.
1998; Mandala et al. 1998) and others (Ohnuki
et al. 2009). Unfortunately, further development of
these inhibitors stalled, either due to physical prop-
erties, e.g. aureobasidin A is very sparingly soluble
in water (Georgopapadakou, 2000; Sugimoto et al.
2004), or because their highly complex chemical
structures rendered chemical synthesis challenging,
with the few synthetic efforts reported resulting in
compounds with either reduced or no activity
(Sugimoto et al. 2004; Aeed et al. 2009). However,
recent works have highlighted that semi-synthetic
strategies may overcome these barriers (Wuts et al.
2015).
Perhaps reflecting the evolutionary divergence of
these enzymes, the protozoan IPC synthase ortholo-
gues, from Leishmania major and T. gondii are not
susceptible to AbA inhibition (Denny et al. 2006;
Pratt et al. 2013). Some studies have reported the
inhibitory effects of AbA and analogues against
T. gondii in culture (Sonda et al. 2005; Alqaisi
et al. 2017), however this is not associated with
inhibition of SL biosynthesis. Despite this, the
protozoan SLS’s remain tractable drug targets with
no functional equivalent in mammalian cells.
Surprisingly, at least one SLS isoform from
T. brucei was acutely sensitive to AbA treatment
(Mina et al. 2009), although these findings stirred
some controversy due, in part, to the redundancy
of T. brucei SLSs (4 isoforms) compared with the
single copy found, for example, in L. major and
T. gondii (Sutterwala et al. 2008).
THE ENIGMATIC NATURE OF SL DRUGGABILITY
Difficulties in pinpointing SL functionality
Investigation and deciphering of the functions of
each specific SL species remains challenging. This is
due to the complexity in SL metabolic interconnec-
tions, their varied biophysical properties (neutral or
charged), chain length variation, the hydrophobic
nature of the involved enzymes and the presence of
multiple pathways that can operate in parallel
(Hannun & Obeid, 2008). The interaction with
other cellular metabolic pathways (e.g. glycerolipid
metabolism) introduces another layer of complexity.
Overall, the signalling effect/role of an individual
SL could be defined on spatial-temporal basis with
at least five parameters: (a) subcellular localisation,
(b) regulation (c) chain length specificity, (d) kinetics
of trafficking and (e) mechanism of action. For
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example, phosphorylation of 1–3% cytosolic SPH
may double the levels of S1P that acts on G
protein-coupled receptor (GPCR) to elicit a
specific response in a particular cellular locality for
certain period of time (Hannun & Obeid, 2008).
Such signalling events can be described as a function
of cytosolic S1P that is regulated by S1P Kinase,
with the signal caused through the interaction
of S1P with a GPCR. The elucidation of such
complex systems remains challenging and a compre-
hensive discussion of the issue is beyond the scope of
this review. However, an additional layer of signifi-
cant complexity in terms of the pathogenic protozoa
arises when considering the SL signalling network in
the case of obligate intracellular parasites, where host
SL biosynthesis, and its interaction with parasite de
novo synthesis, must be taken into account.
Parasite–host SL interplay
The intimate parasite–host interaction in terms
of SL metabolism has been well documented; L.
major pathogenic amastigotes isolated frommamma-
lian hosts showed normal IPC levels (Zhang et al.
2005) despite lacking LCB2, a functional SPT and
the ability to synthesis CER de novo. Alterations in
host, macrophage, cell SL biosynthesis upon infec-
tion may compensate for this deficiency (Ghosh
et al., 2001, 2002). These studies suggest a
complex and multifaceted interplay between host
and parasite SL metabolism comprising nutritional
factors and signalling pathways that could modulate
parasite survival and/or host defence (Zhang et al.
2010). Similar observations have been reported in
the apicomplexan parasites (Romano et al. 2013).
This highlights the striking potential of host and
parasite SL modulation as an anti-protozoal target,
as is similarly proposed for pathogenic fungi
(Zhang et al. 2010; Ramakrishnan et al. 2013).
PERSPECTIVE
Classically dissecting the role and locale of critical
enzymatic steps in SL biosynthesis and assessing
the effect on the parasite fitness and virulence
could turn into an overwhelmingly challenging task
aggravated by: the complexity of the metabolic
pathway itself; the ability of the parasite to salvage
(Coppens, 2013), hijack and remodel host SL; and
developmental regulation during the parasitic life
cycle, which adds another layer of intricacy render-
ing the deconvolution of any observed effects
difficult to interpret. Fortunately, many of those
problems can be now overcome with advances in
technology. High resolution localization studies in
protozoan parasites can benefit greatly from new
microscopic techniques such as Airy-scan (Huff,
2015), super-resolution microscopy (Florentino
et al. 2014) and upcoming technologies, e.g. phase-
modulation nanoscopy (Pal, 2015; Ward & Pal,
2017), which can elucidate spatial arrangement of
proteins of interest within the parasite to reveal
potential interaction partners and shed light on
mechanistic features. Similarly, new advances in
chemical probes, and SL analogues in particular,
such as bifunctional lipid technology (Haberkant &
Holthuis, 2014) coupled with high throughput
proteomic (Ramaprasad et al. 2015), could identify
different interaction partners that would help map
the biosynthetic pathway and its critical interactions.
The effects of these probes on the parasite (and
host) cell can now be comprehensively evaluated
by monitoring the transcriptome, proteome, meta-
bolomics (Watson, 2010) and lipidome (Marechal
et al. 2011). Such studies could reveal multiple
windows of opportunity to exploit as potential
drug targets. The targets identified in this way
can now be rapidly genetically validated in the
parasitic protozoa by applying modern gene
editing technologies, such as CRISPR/Cas9
(Sugi et al. 2016). Compared with the classical
methodologies, this tool enables fast and efficient
application for single gene (Serpeloni et al. 2016),
and systematic genome-wide knockout generation
(Sidik et al. 2016). Additionally, the development
of novel orthogonal approach for conditional
knockout strategies, e.g. tetracycline-induced gene
disruption Tet-system (Meissner et al. 2002),
rapamycin-induced Cre recombinase-assisted gene
excision (Andenmatten et al. 2013; Collins et al.
2013; Jimenez-Ruiz et al. 2014), has allowed
testing of essential gene functionality, in Leishmania
spp. (Duncan et al. 2016) and T. gondii (Pieperhoff
et al. 2015).
Aside from the increase ability to robustly validate
targets such as SL biosynthesis, global collaboration
between academia and pharmaceutical partners is
expediting the process of drug discovery of new
anti-protozoal drugs. For example, within the
sphere of targeting SL biosynthesis in the protozoa,
we have managed several projects with industrial
partners, MRCT and Tres Cantos Open Lab
Foundation (https://www.openlabfoundation.org,
an initiative of GlaxoSmithKline), in the pursuit of
identifying new compound scaffolds active against
the Leishmania spp IPC synthase utilising yeast
(Norcliffe et al. 2014) as a vehicle for drug discovery
(Denny & Steel, 2015). The generated results and
techniques could readily be translated to other
disease targets. Other global initiatives include
Open Innovation Drug Discovery, Eli Lilly, which
is focused on cancer, cardiovascular disease, endo-
crine disorders, neuroscience and tuberculosis. The
Centers for Therapeutic Innovation, facilitates
Pfizer and academic researchers to work together in
order to develop new biologics programs and
WIPO Re:Search, provide participant researchers
with access to patents and expertise related to drug
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discovery for 19 NTDs, malaria and tuberculosis
(Sheridan, 2011).
Finally, SL biosynthesis represents a gold mine
for new drug targets alongside at least two axes, de
novo synthesis and salvage and remodelling. On
one hand, the protozoan de novo SL biosynthetic
pathway comprises three key steps, and considering
their divergence compared with the mammalian
host, identifying specific inhibitors for those could
open an opportunity for anti-protozoal drugs with
synergistic effects and lower incidences of resistance.
On the other hand, the nature of obligate intracellu-
lar parasites dictates that further efforts should be
directed towards the catabolic/salvage pathway
where parasite–host dependencies could be exploited
in order to identify additional key steps, or host
enzymes, where inhibitors would exert further syn-
ergism with the de novo inhibitors.
To summarize, the landscape of anti-protozoan
drug discovery requires immediate attention: with
the re-evaluation of knowledge gained, the applica-
tion of recent technologies; and the support of coor-
dinated global discovery efforts. The multifaceted
effects of SLs as a dynamic matrix of interaction
(spatial and temporal) and function makes SL bio-
synthesis highly alluring for drug intervention,
after all, everybody needs SLs, right?
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